Hepatotoxicity associated with the use of anti-TNF-α agents

Drug Safety

Volumn 39, Issue 3, 2016, Pages 199-208

  French, Joshua B ^a   Bonacini, Maurizio ^b   Ghabril, Marwan ^c   Foureau, David ^d   Bonkovsky, Herbert L ^a,e,f  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b SUTTER HEALTH   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LEVINE CANCER INSTITUTE   (United States)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR;

AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; CLINICAL OUTCOME; DISEASE ASSOCIATION; DRUG USE; HUMAN; LIVER INJURY; LIVER PROTECTION; LIVER TOXICITY; NONHUMAN; PATHOGENESIS; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; TOXIC HEPATITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL AND DRUG INDUCED LIVER INJURY; METABOLISM;

ANIMALS; CHEMICAL AND DRUG INDUCED LIVER INJURY; ETANERCEPT; HUMANS; INFLIXIMAB; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85006992291     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0366-9     Document Type: Review

References (63)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72(9):3666–70.
2. Dayer JM. The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine. 2002;69(2):123–32.
3. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214(2):149–60.
4. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651–65.
5. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–35.
6. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174474.htm. Accessed 15 Oct 2015.
7. http://www.fda.gov/ohrms/DOCKETS/ac/03/briefing/3930B1_04_A-Centocor-Remicade%20.pdf. Accessed 15 Oct 2015.
8. Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558–64.e3.
9. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum. 2008;38(3):208–17.
10. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol. 2006;21(9):1366–71.
11. Garcia Aparicio AM, Rey JR, Sanz AH, Alvarez JS. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol. 2007;26(5):811–3.
12. Thiefin G, Morelet A, Heurgue A, Diebold MD, Eschard JP. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine. 2008;75(6):737–9.
13. Humira (adalimumab). 2015. http://www.rxabbvie.com/pdf/humira.pdf. Accessed 15 Oct 2015.
14. Enbrel (etanercept). 2013. http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf. Accessed 15 Oct 2015.
15. Remicade (infliximab). 2015. http://www.remicade.com/shared/product/remicade/prescribing-information.pdf. Accessed 15 Oct 2015.
16. Simponi (golimumab). 2013. http://www.simponi.com/shared/product/simponi/prescribing-information.pdf. Accessed 15 Oct 2015.
17. Cimzia (certolizumab). 2013. http://www.cimzia.com/assets/pdf/Prescribing_Information.pdf. Accessed 15 Oct 2015.
18. Feuerstein JD, Cheifetz AS. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). Gastroenterol Clin North Am. 2014;43(3):543–63.
19. Ribeiro LB, Rego JC, Estrada BD, Bastos PR, Pineiro Maceira JM, Sodre CT. Alopecia secondary to anti-tumor necrosis factoralpha therapy. An Bras Dermatol. 2015;90(2):232–5.
20. Tong Q, Cai Q, de Mooij T, Xu X, Dai S, Qu W, et al. Adverse events of anti-tumor necrosis factor alpha therapy in ankylosing spondylitis. PLoS One. 2015;10(3):e0119897.
21. Bonacini M, Ghabril M, Bonkovsky HL. Hepatotoxicity of anti- TNF agents. Dig Dis Sci. 2014;59(5):1070–1.
22. US Food and Drug Administration [FDA] Center for Drug Evaluation and Research. FDA briefing document. Arthritis Advisory Committee. FDA. 2003. http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3930T1.htm. Accessed 15 Oct 2015
23. Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med. 2010;5(3):193–200.
24. Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc. 2001;76(1):84–6.
25. Tobon GJ, Canas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol. 2007;26(4):578–81.
26. Parekh R, Kaur N. Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature. Case Rep Gastrointest Med. 2014;2014:956463.
27. Björnsson ES, Gunnarsson BI, Grondal G, Jonasson JG, Einarsdottir R, Ludviksson BR, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015;13(3):602–8.
28. Rossi RE, Parisi I, Despott EJ, Burroughs AK, O’Beirne J, Conte D, et al. Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management. World J Gastroenterol. 2014;20(46):17352–9.
29. Shelton E, Chaudrey K, Sauk J, Khalili H, Masia R, Nguyen DD, et al. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2015;41(10):972–9.
30. Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology. 2008;48(4):1175–83.
31. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf Causality Assessment Method. Hepatology. 2010;51(6):2117–26.
32. Kim E, Bressler B, Schaeffer DF, Yoshida EM. Severe cholestasis due to adalimumab in a Crohn’s disease patient. World J Hepatol. 2013;5(10):592–5.
33. Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis. 2005;64(10):1519–20.
34. Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust. 2007;187(9):524–6.
35. Saleem G, Li SC, MacPherson BR, Cooper SM, et al. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-doublestranded DNA antibodies following infliximab therapy: comment on the article by Charles. Arthritis Rheum. 2001;44(8):1966–8.
36. Rodrigues S, Lopes S, Magro F, Cardoso H, Horta EVAM, Marques M, et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases. World J Gastroenterol. 2015;21(24):7584–8.
37. Grasland A, Sterpu R, Boussoukaya S, Mahe I. Autoimmune hepatitis induced by adalimumab with successful switch to abatacept. Eur J Clin Pharmacol. 2012;68(5):895–8.
38. Perdan-Pirkmajer K, Hocevar A, Rotar Z, Zibert J, Marolt VF, Gucev F, et al. Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: two case reports and an analysis of the laboratory data from the Slovenian National Biologicals Registry. Rheumatol Int. 2013;33(11): 2885–8.
39. Titos-Arcos JC, Hallal H, Robles M, Andrade RJ. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. Rev Esp Enferm Dig. 2012;104(5):282–4
40. van Casteren-Messidoro C, Prins G, van Tilburg A, Zelinkova Z, Schouten J, de Man R. Autoimmune hepatitis following treatment with infliximab for inflammatory bowel disease. J Crohns Colitis. 2012;6(5):630–1.
41. Colina F, Molero A, Casis B, Martinez-Montiel P. Infliximabrelated hepatitis: a case study and literature review. Dig Dis Sci. 2013;58(11):3362–7.
42. Rojas-Feria M, Castro M, Suarez E, Ampuero J, Romero-Gomez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013;19(42):7327–40.
43. Rösner S, Schad A, Kittner J, Rahman F, Worns MA, Schuchmann M, et al. Drug-induced liver injury with an autoimmune phenotype following anti-TNF therapy—presentation of cases and review of literature [in German]. Z Gastroenterol. 2014;52(1):58–63.
44. Cheng FK, Bridges EE, Betteridge JD. Drug-induced liver injury from initial dose of infliximab. Mil Med. 2015;180(6):e723–4.
45. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011;306(21):2331–9.
46. Park KT, Sin A, Wu M, Bass D, Bhattacharya J. Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience. Inflamm Bowel Dis. 2014;20(7):1242–9.
47. Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther. 2012;29(3):234–48.
48. IMS Institute for Healthcare Informatics. Medicine use and shifting costs of healthcare: a review of the use of medicines in the United States in 2013. Danbury: IMS Health Incorporated; 2014.
49. Express Scripts®. The 2014 drug trend report. Express Scripts Holding Company. 2015. http://lab.express-scripts.com/drugtrend- report/. Accessed 15 Oct 2015
50. Grigoriev I, zu Castell W, Tsvetkov P, Antonov AV. AERS Spider: an online interactive tool to mine statistical associations in adverse event reporting system. Pharmacoepidemiol Drug Saf. 2014;23(8):795–801.
51. Efe C, Purnak T, Ozaslan E, Ozbalkan Z, Karaaslan Y, Altiparmak E, et al. Autoimmune liver disease in patients with systemic lupus erythematosus: a retrospective analysis of 147 cases. Scand J Gastroenterol. 2011;46(6):732–7.
52. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus. 2005;14(12):931–7.
53. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014;89(1):95–106.
54. Foureau DM, Walling TL, Maddukuri V, Anderson W, Culbreath K, Kleiner DE, et al. Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol. 2015;180(1):40–51.
55. Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants— past, present and future. Cytokine Growth Factor Rev. 2014;25(4):453–72.
56. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford, England). 2010;49(7):1215–28.
57. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. Monoclon Antib. 2010;2(3):256–65.
58. Brenndorfer ED, Weiland M, Frelin L, Derk E, Ahlen G, Jiao J, et al. Anti-tumor necrosis factor alpha treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C. Hepatology. 2010;52(5):1553–63.
59. Jones BE, Lo CR, Liu H, Srinivasan A, Streetz K, Valentino KL, et al. Hepatocytes sensitized to tumor necrosis factor-alpha cytotoxicity undergo apoptosis through caspase-dependent and caspase-independent pathways. J Biol Chem. 2000;275(1): 705–12.
60. Carvalheiro J, Mendes S, Sofia C. Infliximab induced liver injury in Crohn’s disease: a challenging diagnosis. J Crohns Colitis. 2014;8(5):436–7.
61. Dang LJ, Lubel JS, Gunatheesan S, Hosking P, Su J. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. Australas J Dermatol. 2014;55(1):75–9.
62. Kinnunen U, Farkkila M, Makisalo H. A case report: ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis. J Crohns Colitis. 2012;6(6):724–7.
63. Frider B, Bruno A, Ponte M, Amante M. Drug-induced liver injury caused by adalimumab: a case report and review of the bibliography. Case Rep Hepatol. 2013;2013:406901.